|
KMID : 1001020190170010048
|
|
Journal of Urologic Oncology
2019 Volume.17 No. 1 p.48 ~ p.59
|
|
|
The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea
|
|
Ha Yoon-Soo
Ha U-Syn
Jung Jin-Woo
Park Bong-Hee
Kim Hyung-Joon
Kim Ki-Hong
Yeo Jeong-Kyun
|
|
|
Abstract
|
|
|
|
The treatment of advanced prostate cancer has rapidly evolved. Androgen deprivation therapy is recognized as the first-line therapy for metastatic disease; however, a substantial proportion of patients will eventually progress to develop castration-resistance. For the past several years, docetaxel-based chemotherapy has shown significant therapeutic benefit in castration-resistant prostate cancer. Over the last 5 years, several new agents such as the enzalutamide, abiraterone, cabazitaxel, and 223radium have been developed which have all been associated with improved quality of life, pain palliation, and an increase in survival. Unfortunately, there are no Korean treatment guideline for metastatic prostate cancer and/or castration-resistant prostate cancer which has been developed based on adequate review and assessment of evidences. Thus, a guideline adequate for domestic circumstances is eagerly needed. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines.
|
|
|
KEYWORD
|
|
|
Prostatic neoplasms, Castration-resistant, Korea
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|